Headquartered in Lawrence, Massachusetts, NxStage Medical (NXTM) is a medical technology company with a focus on developing, manufacturing, and marketing innovative products targeted at patients suffering from chronic or acute kidney failure.
The company also operates NxStage kidney care dialysis centers, which treat end-stage renal disease (or ESRD) patients. The company sells its products and offers services in three markets: home, critical care, and in-center.
NxStage Medical’s primary product is System One, which is capable of delivering the therapeutic flexibility and clinical benefits of traditional dialysis machines in a smaller, portable, and easy-to-use format. The system can be used by healthcare professionals as well as lay-users at hospitals, dialysis centers, and patient homes. Along with System One, NxStage Medical also sells blood tubing sets and needles to dialysis clinics and hospitals for use with traditional dialysis machines.
All eight of the analysts covering NxStage Medical in February 2018 have given the stock “hold” ratings. The mean rating for the stock is 3, and its target price is $29.88.
Of the ten analysts covering Abiomed (ABMD) in February 2018, five analysts have given the stock “strong buy” ratings, and three analysts have given it “buy” ratings. Two analysts have given it “hold” ratings. The mean rating for the stock is 1.7 with a target price of $281.22.
Of the 17 analysts covering Baxter International (BAX) in February 2018, ten have given the stock “buy” or higher ratings. Six analysts have given it “hold” ratings, and one analyst has given it a “sell” rating. The mean rating on the stock is 2.29, and it has a target price of $75.27.
Of the 16 analysts covering Insulet (PODD) in February 2018, ten have given the stock “buy” or higher ratings, while six have given it “hold” ratings. The mean rating for the stock is 2.06, and its target price is $74.38.
In the next part of the series, we’ll take a look at the proposed merger of NxStage Medical and Fresenius Care Holdings.